MRNA is trading 5% down at $45.69 as rising Treasury yields and a risk-off market tone weigh on the biotech sector.
- Shares are sliding alongside broader weakness in growth and high-risk names as long-term rates continue to climb.
- There is no major company-specific news driving the move; the decline is attributed to macro uncertainty and sector rotation.